Update: Amgen v. Hospira
By EsqSocial Corporation 24/10/17
As we previously reported, on September 22, 2017, a Delaware federal jury awarded Amgen $70 million in damages after finding that Hospira infringed one of Amgen’s Epogen® (EPO) patents (the ’298 patent). Five days later, Hospira filed a motion under...
By: Goodwin